Strong IM8-led growth: Second-quarter revenue reached $46.5 million, up 29% sequentially, with IM8 contributing $45 million at a 65% gross margin. Prenetics raised its 2026 revenue outlook to $220 million–$230 million and introduced a 2027 target of at least $400 million. Customer acquisition and cash flow improved: IM8 added 118,000 customers in Q2 and ended the period with 140,000 active subscribers; July acquisition costs fell 21% to about $239.
The company reported its first positive consolidated adjusted free cash flow in July, including General Catalyst financing, while expecting second-half adjusted EBITDA losses to narrow substantially. Expansion plans continue: IM8 plans to launch hydration products in Q4 and premium gummies in Q1 2027, neither of which is included in current guidance. Prenetics also has three ongoing randomized clinical studies, with results expected primarily in 2027.
Prenetics Global (NASDAQ:PRE) reported second-quarter revenue of $46.5 million, up 29% sequentially and about 3.9 times from a year earlier, as its IM8 supplement business continued to add subscribers and scale marketing spending. The company raised its full-year revenue outlook and said July marked its first month of positive consolidated adjusted free cash flow, including funding provided under its General Catalyst facility. The webcast was the company's first live earnings video presentation.
Management said it released a 40-page shareholder letter and an 80-page investor deck detailing cohort performance, acquisition costs and retention data. → AMG's Alternatives Boom Powers Record Growth IM8 generated $45 million of second-quarter revenue, while total Prenetics revenue reached $46.5 million, within the company's prior guidance ranges. IM8 revenue rose 33% from the first quarter and carried a 65% gross margin, according to management. The company raised its 2026 total revenue guidance to $220 million to $230 million, including IM8 revenue of $215 million to $222 million.
For the third quarter, Prenetics forecast total revenue of $63 million to $64 million, with IM8 contributing $61.5 million to $62.5 million. → Microsoft's Maia 300 Chip Targets NVIDIA's AI Dominance Management said the full-year outlook implies approximately $81.2 million in fourth-quarter revenue at the top end of the range. It also introduced a 2027 revenue outlook of at least $400 million and said it expects to exit 2026 at an annualized revenue run rate above $300 million. In July, Prenetics reported preliminary total revenue of $21.4 million, including roughly $20.9 million from IM8.
Management said the month represented the company's highest monthly revenue level and was equivalent to an annualized run rate of about $251 million. → The Metals Company's Big Bet Now Comes Down to a License Brian Rosin, U.S. CFO of Prenetics, said the company acquired 118,000 new IM8 customers in the second quarter, a 98% increase from the prior quarter. Customer acquisition cost was flat to slightly lower sequentially despite a significant increase in acquisition spending.
Extract — continue reading at the source.
